跳至主要内容
临床试验/NCT02860481
NCT02860481终止不适用

FSH-R (Follicle-stimulating Hormone Receptor ): Diagnostic Application for Localized Tumors in Cancerology

Institut Curie4 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
95
试验地点
4
主要终点
sensitivity of blood FSH R detection in cancer patients

研究概览

简要总结

FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the diagnosis of cancer.

A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will include n=10 patients per histological type except for breast cancer (n=50). 100 patients are expected in this cohort.

A second cohort will explore the more promising histological type (if any) in term of incidence of detection. 100 patients are expected for this second cohort.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

sensitivity of blood FSH R detection in cancer patients

时间窗: end of the study, up to two years

次要结局

  • comparison of blood FSH-R with blood from healthy donor(end of the study, up to two years)
  • variability of blood FSH-R in the same tumoral type and between different tumoral types(end of the study, up to two years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

FSH-R : Diagnostic Application for Localized Tumors... | 临床试验